Monitor for future clinical milestones on Entolimod (ARS) and potential expansion into oncology supportive care. No immediate catalyst from this leadership profile piece.
Price Chart
Executive Summary
Valion Bio issued a press release highlighting the expertise of new Board Chair Thomas Jensen, who brings biotech turnaround experience from Allarity Therapeutics. The filing is a routine leadership communication with no financial data or material corporate action.
Key Facts
- Thomas H. Jensen became Board Chair in September 2026.
- Jensen is CEO and Director of Nasdaq-listed Allarity Therapeutics, Inc.
- Entolimod has received approximately $35.6 million in non-dilutive government funding.
- Entolimod holds FDA Fast Track and Orphan Drug designations for acute radiation syndrome (ARS).
- Valion owns a wholly owned U.S.-based CDMO, Velocity Bioworks.
Financial Impact
No financial impact; $35.6 million in non-dilutive funding for Entolimod is disclosed but not new in this filing.
Risk Factors
- Clinical-stage biotech with no approved products; Entolimod development depends on FDA Animal Rule pathway.
- No revenue disclosed; company relies on non-dilutive funding and capital markets.
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032107 |
| Exhibit: ex_1022416.htm | 0001437749-26-032107 |
| Document: 0001437749-26-032107-index-headers.html | 0001437749-26-032107 |
| Document: 0001437749-26-032107-index.html | 0001437749-26-032107 |
| Document: 0001437749-26-032107.txt | 0001437749-26-032107 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.8950 | awaiting T+20 | — | $0.7820 (+12.63%) |
Oct 26, 2026 1d ago | 8-K | $0.8400 | awaiting T+20 | — | $0.7820 (−6.90%) |
Oct 22, 2026 5d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.7820 (−18.20%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.7820 (+30.18%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.7820 (+30.18%) |
Oct 16, 2026 11d ago | S-3 | $1.16 | awaiting T+20 | — | $0.7820 (+32.59%) |
Oct 16, 2026 11d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.7820 (+32.59%) |
Oct 15, 2026 12d ago | 8-K | $1.23 | awaiting T+20 | — | $0.7820 (−36.42%) |
Oct 14, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $0.7820 (−46.07%) |
Oct 8, 2026 19d ago | 8-K | $2.21 | awaiting T+20 | — | $0.7820 (+64.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers